Page last updated: 2024-11-02

oxidopamine and Huntington Disease

oxidopamine has been researched along with Huntington Disease in 13 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

ExcerptRelevanceReference
"In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time."1.48Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018)
"Huntington's disease is an autosomal dominant hereditary neurodegenerative disorder characterized by severe striatal cell loss."1.31Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. ( Brundin, P; Castilho, RF; DiFiglia, M; Hansson, O; Petersén, A; Przedborski, S; Puschban, Z; Rice, M; Romero, N; Sapp, E; Sulzer, D, 2001)
"Adenosine A2 receptors were labeled and visualized by autoradiography in tissue sections of the human brain using the A2-selective agonist ligand [3H](2-p-(2-carboxyethyl)phenylamino)-5'-N-carboxamidoadenosine (CGS 21680)."1.28Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. ( Martinez-Mir, MI; Palacios, JM; Probst, A, 1991)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (30.77)18.2507
2000's5 (38.46)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, S1
Tereshchenko, J1
Zimmer, V1
Vachey, G1
Pythoud, C1
Rey, M1
Liefhebber, J1
Raina, A1
Streit, F1
Mazur, A1
Bähr, M1
Konstantinova, P1
Déglon, N1
Kügler, S1
Choi, ML1
Begeti, F1
Oh, JH1
Lee, SY1
O'Keeffe, GC1
Clelland, CD1
Tyers, P1
Cho, ZH1
Kim, YB1
Barker, RA1
Vandeputte, C1
Taymans, JM1
Casteels, C1
Coun, F1
Ni, Y1
Van Laere, K1
Baekelandt, V1
Sheline, CT1
Zhu, J1
Zhang, W1
Shi, C1
Cai, AL1
Olds, ME1
Jacques, DB1
Kopyov, O1
de Lago, E1
Fernández-Ruiz, J1
Ortega-Gutiérrez, S1
Cabranes, A1
Pryce, G1
Baker, D1
López-Rodríguez, M1
Ramos, JA1
Reynolds, DS1
Carter, RJ1
Morton, AJ1
Hebb, MO1
Robertson, HA1
Guzman, R1
Lövblad, KO1
Meyer, M1
Spenger, C1
Schroth, G1
Widmer, HR1
Levivier, M1
Donaldson, D1
Petersén, A1
Hansson, O1
Puschban, Z1
Sapp, E1
Romero, N1
Castilho, RF1
Sulzer, D1
Rice, M1
DiFiglia, M1
Przedborski, S1
Brundin, P1
Burton, S1
Daya, S1
Potgieter, B1
Martinez-Mir, MI1
Probst, A1
Palacios, JM1

Other Studies

13 other studies available for oxidopamine and Huntington Disease

ArticleYear
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
    Experimental neurology, 2018, Volume: 309

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression

2018
Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
    Neurobiology of disease, 2014, Volume: 66

    Topics: Animals; Brain; Corpus Striatum; Dentate Gyrus; Dopamine; Dopamine Antagonists; Female; Hippocampus;

2014
Automated quantitative gait analysis in animal models of movement disorders.
    BMC neuroscience, 2010, Aug-09, Volume: 11

    Topics: Animals; Automation; Brain; Disease Models, Animal; Female; Gait; Huntington Disease; Intracranial T

2010
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
    Neuro-degenerative diseases, 2013, Volume: 11, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins;

2013
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
    Synapse (New York, N.Y.), 2005, Volume: 55, Issue:1

    Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal;

2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D

2006
Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998, Dec-01, Volume: 18, Issue:23

    Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzazepines; Corpus Striatum; Disease Models, A

1998
Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases.
    The Journal of comparative neurology, 1999, Jul-19, Volume: 410, Issue:1

    Topics: Animals; Behavior, Animal; Brain; Brain Mapping; Corpus Striatum; Dextroamphetamine; Disease Models,

1999
Imaging the rat brain on a 1.5 T clinical MR-scanner.
    Journal of neuroscience methods, 2000, Apr-01, Volume: 97, Issue:1

    Topics: Animals; Artifacts; Blood-Brain Barrier; Brain; Brain Tissue Transplantation; Female; Huntington Dis

2000
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
    Neurological research, 2000, Volume: 22, Issue:4

    Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin

2000
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.
    The European journal of neuroscience, 2001, Volume: 14, Issue:9

    Topics: Aging; Animals; Ascorbic Acid; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Respons

2001
Melatonin modulates apomorphine-induced rotational behaviour.
    Experientia, 1991, May-15, Volume: 47, Issue:5

    Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun

1991
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.
    Neuroscience, 1991, Volume: 42, Issue:3

    Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Hu

1991